Nycomed Files NDA For Daxas; Still Seeks U.S. Marketing Partner For Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Daxas shows positive effect on exacerbations in patients with chronic obstructive pulmonary disease in pivotal studies; final data expected in September.
You may also be interested in...
Nycomed Reviewing Bids For U.S. Partners For Daxas
Bidding ended last week for potential U.S. partners for Nycomed’s new COPD drug, and the vetting process is under way.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.